Investor Service Announcement no. 4/2011
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, August 5, 2011
Veloxis Pharmaceuticals A/S to Present at the Cannacord Genuity Annual Growth Conference
Veloxis Pharmaceuticals A/S (OMX: VELO), formerly LifeCycle Pharma A/S, today announced that William J. Polvino, M.D., President and Chief Executive Officer, will present at the Canaccord Genuity Annual Growth Conference at 4 p.m. EDT on Tuesday, August 9, at the InterContinental Hotel in Boston. Dr. Polvino will provide an overview of the company and its lead Phase 3 candidate, LCP-Tacro™, to prevent organ transplant rejection. He will also discuss recently-announced top-line results of the first Phase 3 trial in stable kidney transplant patients.
For more information, please contact:
|
Veloxis Pharmaceuticals A/S John Weinberg, M.D. SVP, Commercial Operations & Investor Relations Phone: +1 908 304 3389 Email: jdw@veloxis.com |
|
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis’ efforts to develop a product portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis’ unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
